Global Adalimumab Biosimilar market is expected to grow at rapid pace with strong presence of major players such as Amgen, Pfizer, Sandoz International GmbH, Boehringer Ingelheim, Celltrion Healthcare Co., Ltd., Samsun Biopesis, Biogen, Hetero Drugs, Kyow

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Adalimumab Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2026'

Request for ToC/Proposal: https://bit.ly/2MEYhxZ

Adalimumab is a first humanized monoclonal antibody indicated for the treatment of various autoimmune diseases. adalimumab is an anti-TNF (tumour necrosis factor) drug that block the action of TNF (tumour necrosis factor) to reduce the inflammation. It is prescribed for the treatment of diseases such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. It was first discovered by “phage display” technique which was named D2E7. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation. In January 2013, Abbott Laboratories separated its pharma business named as AbbVie Inc. which was further involved in development and commercializing activities. AbbVie marketed Adalimumab product under the trade name of Humira. It was approved by U.S. Food Drug and Administration (FDA) in 2008 and by European Medicines Agency in 2003. However, the patent on Humira has expired in Europe in June 2017 and in the U.S. in November 2017. It is world’s best-selling drug thus several pharmaceutical companies are focusing on the development of biosimilar adalimumab products.

The adalimumab biosimilar market is fragmented/consolidated with presence of many/few players that operates in local as well as international market.
Global adalimumab biosimilar Market reports cover prominent players like Amgen, Pfizer, Sandoz International GmbH, Boehringer Ingelheim, Celltrion Healthcare Co., Ltd., Samsun Biopesis, Biogen, Hetero Drugs, Kyowa Hakko Kirin, LG Life Sciences, Mochida Pharmaceutical, and Momenta Pharmaceuticals.

Curious about this latest version of report?
Obtain Report Details @ https://bit.ly/2MEYhxZ

Market Segments
• Global Adalimumab Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Application
o Crohn’s Disease
o Psoriatic Arthritis
o Rheumatoid Arthritis
o Ulcerative Colitis
o Ankylosing Spondylitis
o Plaque Psoriasis and other

• Global Adalimumab Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Distribution Channel
o Hospital Pharmacy
o Online Pharmacy
o Retail Pharmacy
o Other Direct Distribution Channels

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global adalimumab biosimilar market
 To receive industry overview and future trends adalimumab biosimilar market
 To analyze the adalimumab biosimilar market drivers and challenges
 To get information on adalimumab biosimilar market size and forecast
 To get details on adalimumab biosimilar clinical trial/pipeline analysis
 Originator drug historic revenue
 Originator drug key news/industry activities
 Major Mergers & Acquisition in adalimumab biosimilar industry

For More Information @ https://bit.ly/2MEYhxZ

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Email us: info@insightaceanalytic.com
Call us: +1 718 593 4405
Pune, Maharashtra 411004

This release was published on openPR.